Other Clinical Trial - Apatinib Plus Camrelizumab Combined With Docetaxel

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT01142388` - Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer	Phase 2
Active, not recruiting	`NCT03337087` - Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT03641313` - Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer	Phase 2
Not yet recruiting	`NCT05342389` - Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer	Phase 2
Recruiting	`NCT05733000` - CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors	Phase 2
Recruiting	`NCT05651594` - Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma	Phase 2
Recruiting	`NCT05269381` - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors	Phase 1
Recruiting	`NCT04511039` - Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer	Phase 1
Not yet recruiting	`NCT04921904` - Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca	Phase 1/Phase 2
Recruiting	`NCT04660760` - Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer	Phase 2
Not yet recruiting	`NCT06203600` - Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, The PARAMMUNE Trial	Phase 2/Phase 3
Active, not recruiting	`NCT05555251` - BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT04840264` - Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction	Phase 2
Recruiting	`NCT05677490` - mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma	Phase 3
Completed	`NCT02391038` - MLN0264 in Previously Treated Asian Patients With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C	Phase 1/Phase 2
Completed	`NCT03395847` - Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma	Early Phase 1
Active, not recruiting	`NCT03008278` - Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery	Phase 1/Phase 2
Recruiting	`NCT06329973` - Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer	Phase 1/Phase 2
Recruiting	`NCT05041153` - Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma	Early Phase 1
Recruiting	`NCT04007744` - Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	Phase 1

NCT number	NCT04781686
Study type	Interventional
Source	Zhongnan Hospital
Contact	Fuxiang Zhou, M.D.
Phone	+86-027-67813155
Email	happyzhoufx@sina.com
Status	Recruiting
Phase	Phase 2
Start date	May 14, 2021
Completion date	August 2025

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms